Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958776 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
A Phase 3 study, sponsored by BioCryst Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
NCT00958776 is a Phase 3 study that was terminated before completion, run by BioCryst Pharmaceuticals. The registered enrollment target is 405 participants.
The verdict
NCT00958776, a Phase 3 study, was terminated before completion, sponsored by BioCryst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
Study Summary
A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.
Interventions
- DRUG Peramivir+SOC
- DRUG Placebo+SOC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958776
The ClinicalTrials.gov registry entry for NCT00958776 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Peramivir+SOC is the first listed.
NCT00958776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00958776 about?
NCT00958776 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza". A Phase 3, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of peramivir administered intravenously in addition to standard of care compared to standard of care alone in adults and adolescents who are hospitalized due to serious influenza.
What is the current status of trial NCT00958776?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2009-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00958776?
The interventions under investigation include: Peramivir+SOC (DRUG), Placebo+SOC (DRUG).
Who is sponsoring clinical trial NCT00958776?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.